Parkinson Disease
Conditions
Interventions
Forty-two participants will be randomly assigned to the Control Group (CG) (21 participants) or the Experimental Group (GE) (21 participants). Both interventions will last for 12 weeks, with a frequen
Other
E02.190.525.186
G11.427.410.698.277
Sponsors
Instituto de Ciências da Saúde da Universidade Federal da Bahia
Clínica Escola de Fisioterapia
Eligibility
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Being on regular medication for Parkinson's disease; being on the medication "on" period; have age greater than or equal to 50 and less than or equal to 80 years; present stage 2, 2.5 or 3 according to the Hoehn and modified Yahr classification.
Exclusion criteria
Exclusion criteria: To present neurodegenerative diseases excluding Parkinson's disease; osteomioarticular diseases that make it impossible to practice physical activity; chronic non-controlled diseases (hypertension, diabetes mellitus, chronic pain); unstable cardiovascular diseases (acute heart failure, recent myocardial infarction, unstable angina and uncontrolled arrhythmias); use of alcohol and other toxic substances; practicing or practicing a physical exercise program in the last 6 months; or participate in or participate in regular resistance training (2-3 times per week) in the previous 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased forced expiratory volume in one second (FEV1), verified by spirometry, from the finding of a variation of at least 5% in pre and post intervention measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| Forced Vital Capacity (FVC), verified by spirometry, from the finding of a variation of at least 5% in pre and post intervention measurements. ;FEV1 / FVC ratio, verified by spirometry, from the finding of a variation of at least 5% in pre and post intervention measurements.;Maximum inspiratory pressure (Pimax), verified by manovacuometry, from the finding of a variation of at least 5% in the pre and post intervention measurements.;Maximum expiratory pressure (Pemax), verified by manovacuometry, from the finding of a variation of at least 5% in pre and post intervention measurements.;Peak Expiratory Flow (PEF), verified by spirometry, from the finding of a variation of at least 5% in pre and post intervention measurements.;Chest expansion at axillary, xiphoid and umbilical level, verified by measuring with tape, from the finding of a variation of at least 5% in pre and post intervention measurements.;6-minute walk test, verified by the maximum distance covered during 6 minutes, from the finding of a variation of at least 5% in the pre and post intervention measurements.;Stand-up test, verified for the shortest time necessary to stand and sit 5 times, from the finding of a variation of at least 5% in the pre- and post-intervention measurements. | — |
Countries
Brazil
Contacts
Public ContactDaniel Ferraz
Instituto de Ciências da Saúde da Universidade Federal da Bahia
Outcome results
None listed